Recent studies presented at the American Glaucoma Society meeting have highlighted the potential benefits of NCX 470, a nitric oxide-donating bimatoprost eye drop designed to reduce intraocular pressure (IOP) in patients with glaucoma. This innovative treatment appears to offer a dual mechanism of action, enhancing both trabecular meshwork and uveoscleral outflow pathways to effectively lower IOP.
Dr. Sanjay G. Asrani shared findings from the phase 3 DENALI trial, which involved 696 patients diagnosed with glaucoma or ocular hypertension. This study compared the efficacy of NCX 470 to that of latanoprost 0.005%. Results indicated that NCX 470 not only achieved noninferiority compared to latanoprost but also demonstrated statistically significant greater reductions in IOP during afternoon assessments at weeks 2 and 6, with sustained efficacy observed over a three-month period.
Asrani noted, “It provided a rapid, robust, and consistent IOP lowering over three months with statistically greater reductions at three of the six time points. It was safe and well tolerated, with low and comparable discontinuation rates between the treatment groups.” This underscores NCX 470’s promising profile as a well-tolerated option for patients managing glaucoma.
Mechanism of Action
Further insights were provided by Dr. Arthur J. Sit and colleagues, who conducted a phase 3b clinical trial assessing the effects of NCX 470 on aqueous humor dynamics. This study involved 18 subjects, with four diagnosed with ocular hypertension, comparing the treatment with a placebo in the contralateral eye. Sit’s findings revealed that NCX 470 improved outflow facility significantly, with measurements increasing from a baseline of 0.283 ± 0.074 µL/min/mm Hg to 0.332 ± 0.087 µL/min/mm Hg by day 8. Notably, this improvement accounted for 42% of the IOP reduction observed.
the uveoscleral outflow rate experienced a significant increase from a baseline of -0.12 ± 0.83 µL/min to 0.44 ± 0.8 µL/min at day 8, which contributed to 58% of the IOP reduction. Sit remarked, “In healthy adults without glaucoma, NCX 470 0.1% dosed once daily does have a significant IOP-lowering effect by a dual mechanism of action, which increases outflow facility and increases uveoscleral outflow.”
Subgroup Analysis
A subgroup analysis of the DENALI trial conducted by Dr. Jason Bacharach included 549 subjects from the United States. The analysis revealed that the signify IOP reduction in the NCX 470 group ranged from 8.1 mm Hg to 10.1 mm Hg at various time points, whereas the latanoprost group exhibited a mean reduction ranging from 7.3 mm Hg to 9.9 mm Hg. The data indicated that NCX 470 provided superior IOP reduction at several time points, reinforcing its effectiveness as a treatment option.
Industry Insights
Doug Hubatsch, Chief Scientific Officer at Nicox, emphasized the importance of these findings, stating, “These data further reinforce results we have previously announced demonstrating the robust intraocular pressure-lowering effect and favorable safety profile of NCX 470. Our clinical data presented validate the dual mechanism of intraocular pressure lowering through the trabecular meshwork and uveoscleral pathways that had previously been shown in animal models.” He also noted that the preplanned analysis of the phase 3 data demonstrates additional differentiation in IOP reduction, with preclinical data suggesting potential benefits in retinal protection.
Conclusion
The emerging data on NCX 470 presents a promising advancement in the treatment landscape for glaucoma, offering patients an effective option for managing their condition. As further studies and clinical trials continue to validate its efficacy and safety, NCX 470 could potentially reshape treatment protocols, providing healthcare providers with a valuable tool in combating glaucoma and its associated risks.
As the medical community awaits further insights and the potential market release of NCX 470, ongoing discussions around effective glaucoma management will be crucial. Stakeholders are encouraged to stay informed about developments in this area, as they could significantly impact patient outcomes.
Note: This article is for informational purposes only and does not constitute professional medical advice.
